加载中
NASDAQHealthcareBiotechnology
最新数据
US$16.5013
−US$0.0487 · -0.29%
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
常规交易时段
US$16.5013
−US$0.0487 · -0.29%
盘中时间采用ET。市场数据可能有所延迟。
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
日内区间
当前US$16.5013
52周区间
当前US$16.5013
盘中时间采用ET。市场数据可能有所延迟。
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
日内区间
当前US$16.5013
52周区间
当前US$16.5013
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.83亿 USD | 2.35亿 USD | 1.76亿 USD | 1.34亿 USD | 4560.5万 USD |
| 销货成本 | 3266.5万 USD | 2824.8万 USD | 1414.8万 USD | 566.4万 USD | 109.1万 USD |
| 毛利 | 2.5亿 USD | 2.07亿 USD | 1.61亿 USD | 1.28亿 USD | 4451.4万 USD |
| 研究与开发 | 3250.5万 USD | 2078.5万 USD | 4964.1万 USD | 4498.8万 USD | 5113.9万 USD |
| 销售、一般及管理费用 | 1.02亿 USD | 1.72亿 USD | 1.95亿 USD | 1.96亿 USD | 1.71亿 USD |
| 营业费用 | 1.45亿 USD | 2.12亿 USD | 2.53亿 USD | 2.4亿 USD | 2.25亿 USD |
| 利息收入 | 1357.3万 USD | 1697万 USD | 1699.7万 USD | 511.8万 USD | 52.9万 USD |
| 利息支出 | 433万 USD | 483.5万 USD | 277.5万 USD | — | — |
| 折旧和摊销 | 927万 USD | 1944.5万 USD | 1164.7万 USD | 270.6万 USD | 276.1万 USD |
| 营业利润 | 1.05亿 USD | −468.7万 USD | −9169.1万 USD | −1.11亿 USD | −1.81亿 USD |
| 净利润 | 2.87亿 USD | 575.2万 USD | −7802万 USD | −1.08亿 USD | −1.81亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$16.00
下跌空间 3.04%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年10月23日 | 1:50 | — | — |
已生效 2013年10月23日
1:50
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM5063.88万0.07%787.4亿 USD0.19%US$276.26-0.59%
iShares Russell 2000 Growth ETFIWO1824.75万0.13%139.17亿 USD0.24%US$350.65-0.87%
iShares Biotechnology ETFIBB1517.33万0.14%108.2亿 USD0.44%US$200.62-1.78%
Vanguard Russell 2000 ETFVTWO1104.37万0.06%180亿 USD0.06%US$111.59-0.61%
Fidelity Enhanced Small Cap ETFFESM766.05万0.12%64.1亿 USD0.28%US$45.02-0.49%
Vanguard Health Care ETFVHT506.04万0.02%220亿 USD0.09%US$316.77-1.22%
Principal U.S. Small-Cap Multi-Factor ETFPSC393.58万0.14%27亿 USD0.38%US$67.56-0.18%
Avantis U.S. Small Cap Equity ETFAVSC313.18万0.10%30.79亿 USD0.25%US$69.875-0.14%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTPrincipal U.S. Small-Cap Multi-Factor ETFPSCAvantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
